[Edaily Reporter Kwon Oh-seok] #Aptabio announced on the 16th that it has received approval from the U.S. Food and Drug Administration (FDA) to lift the clinical hold and resume Phase 1 clinical trials for "ABF-101," an oral treatment for age-related macular degeneration. Following receipt of this official notice, the company plans to resume the previously suspended clinical trials and drug administration.
Disclosure Plus
Aptabio Lifts Hold on Phase 1 Clinical Trial for 'ABF-101'
Kwon Oh Seok
2026-06-16 11:57:54
Economy
Corporation
IT·Science
Economy
[Market In] OGQ Receives Preliminary Technology Evaluation Grade A… Dispute Over Investment Recovery Remains at an Impasse
OGQ, South Korea’s largest intellectual property (IP) content company, which faces the risk of a forced sale of its founder’s shares due to a dispute with existing investors, has received an “A” ratin…
Corporation
“From Character Merchandise to Beauty Shops”… Home Shopping Channels Seek New Revenue Streams Beyond TV
The home shopping industry, whose growth has stalled due to an economic downturn and a shrinking TV market, is seeking new avenues for growth beyond television. The industry is strengthening its onlin…
IT·Science
Samsung Has Expanded Its Organization… But How Will the ‘Physical AI Boom’ Affect Robot Companies’ Earnings?
As SamsungElectronics(005930)has launched a dedicated Physical Artificial Intelligence (AI) organization, major domestic robotics companies are also accelerating their growth. With sales increasing, p…
